Despite the important advances being made in disease-modifying multiple sclerosis (MS) therapies, patients are often affected by a wide variety of symptoms caused by neurologic injury in MS. Common symptoms that patients with MS experience during the course of their illness include weakness, ambulatory impairment, sensory disturbances that may be unpleasant or even painful, ataxia and tremor, bladder and bowel dysfunction, sexual dysfunction, fatigue, spasticity, vertigo, depression and other psychiatric symptoms, cognitive impairment, and paroxysmal symptoms such as cramps, spasms, Lhermitte symptom, and Uhthoff phenomenon. These MS symptoms can cause loss of vocation and social isolation. Neurologic care of patients with MS often involves a greater degree of management of the symptoms caused by MS than appropriate prescription of disease-modifying treatments. In addition, many of the disease-modifying therapies have unpleasant side effects that may also require treatment. This article will focus on medical treatments, use of rehabilitation medicine, and, in select cases, surgical interventions for management of MS symptoms. Continuum Lifelong Learning Neurol 2010;16(5):90-104.
immunomodulatory therapy directed toward the underlying disease process. The symptoms of MS are varied, unpredictable, and generally amenable to management through medications in conjunction with physical therapy and, occasionally, surgical intervention. Typical signs and symptoms that patients with MS might experience are listed in Table 5 -1, and treatments are listed in Table 5 -2.
Spasticity
The spasticity associated with MS often affects the lower extremities to a greater degree than the upper extremities and may manifest as early gait disturbance. Loss of descending inhibitory (-aminobutyric acid-ergic) input into the segmental reflex arcs within the spinal cord results in exaggerated tonic contraction of antagonist and agonist muscles, which limits movements and may result in painful muscle spasms. Spasticity, resulting from upper motor neuron dysfunction, can produce a myriad of subjective symptoms, including stiffness, cramps, spasms, and clonus. Sometimes obtaining a precise history from the patient as to the exact nature of the symptoms may be difficult, making it challenging to come up with a targeted treatment approach. Trial and error may be required to find the appropriate medication to address the symptom. Stretching exercises should be among the first interventions for spasticity and are sometimes sufficient for controlling mild spasticity. More substantial symptoms may be relieved by medications as listed in Table 5 -2. Treatment of spasticity requires individualized treatment with the initial approach based on symptom intensity, frequency, time of day, and patient-specific concerns for side effects. Treatment is initiated at bedtime to limit the sedating side effects and is gradually increased in slow increments. Eventually patients either reach a dose that works or must stop escalating the dose because of sedation, weakness, or other side effects. Sometimes a more frequent dosing regimen of smaller doses reduces the side effects and maximizes the benefits. In addition, gait and transfers sometimes can worsen with reductions in spasticity, particularly if the increased tone was helping with weight bearing. One must balance spasticity that is helpful with daily functioning with spasticity that impedes daily living.
Baclofen (Lioresal) is particularly useful for the relief of flexor spasms and concomitant pain and is recommended in doses up to 80 mg daily, beginning typically with 5 mg 2 times a day and titrating upward to the desired clinical effect of decreased spasticity. 1 In treating spasticity, one typically increases the dosing of baclofen by 5 mg to 10 mg daily at 3-day intervals until the patient 91 A Sometimes obtaining a precise history from the patient as to the exact nature of the symptoms may be difficult, making it challenging to come up with a targeted treatment approach. Trial and error may be required to find the appropriate medication to address the symptom.
A Treatment of spasticity requires individual treatment with the initial approach based on symptom intensity, frequency, time of day, and patient-specific concerns for side effects. Treatment is initiated at bedtime to limit the sedating side effects and is gradually increased in slow increments.
Continuum Lifelong Learning Neurol 2010;16 (5) " SYMPTOMATIC THERAPY notes subjective improvement. Many physicians experienced in the treatment of MS may use doses of 160 mg (and greater) daily. The maximal tolerable dose for each patient is indicated by drowsiness or dizziness, or precipitation of muscle weakness (due to excessive blockade within the spinal cord). If such side effects occur, one may decrease the dosing until these symptoms are alleviated. If baclofen treatment is to be discontinued, it should be tapered off slowly to avoid a withdrawal syndrome, which can lead to seizures and encephalopathy. Tizanidine (Zanaflex), an 2 -receptor agonist has been compared favorably to baclofen in the management of spasticity in MS. The main side effects are sedation and weakness. The sedating effects are more limiting than those of baclofen in some patients. For this reason, titration of tizanidine is done very slowly at rates of 1 mg/d to 2 mg/d and even more slowly in some patients. The typical starting dose is 2 mg each bedtime and is increased to 12 mg/d in three divided doses. If no clinical benefit is achieved at that dose, it can be increased up to 24 mg/d and in some situations up to 36 mg/d. Weakness may not be as pronounced as with baclofen, and therefore tizanidine may be the drug of choice for patients with concomitant weakness and stiffness. Patients already on baclofen should be maintained on baclofen while adding tizanidine, unless side effects are limiting. Once clinical benefit has been achieved, baclofen can be weaned and tizanidine can be increased as needed.
In cases where spasticity is accompanied by painful flexor spasms that are not relieved by baclofen, the addition of dantrolene (Dantrium) is very useful. It is a directly acting skeletal muscle relaxant that interferes with the release of Ca++ from the sarcoplasmic reticulum. Therapy begins with 25 mg/d and may increase by 25 mg/d, typically to total doses of 100 mg/d to 200 mg/d. Hepatotoxicity is a major concern with prolonged use of dantrolene, and liver function tests (ie, aspartate aminotransferase, alanine aminotransferase should be followed regularly. The medication is discontinued if abnormalities occur, and continued long-term use is not advised if benefits are not seen within the first 45 days (see Physicians' Desk Reference). In patients with severe spasticity refractory to oral regimens or those with intolerable side effects, an intrathecal baclofen pump 93 should be considered. This can be extremely effective for lower extremity spasticity and can also improve upper extremity spasticity when higher doses are used. Patients who are nonambulatory with severe spasticity can benefit from intrathecal baclofen, as it can help ease positioning and reduce painful spasms. Botulinum toxin is helpful for focal spasticity but is impractical for more diffuse muscle involvement. Diazepam (Valium) is also a useful adjunct in the treatment of spasticity and may be started at 2 mg 2 times a day, with weekly dosing increases of 2 mg daily. 2 Its use is also limited by sedation and weakness, and by concerns for drug dependency. Gabapentin (Neurontin) may also have some mild benefits in the treatment of spasticity. 3 Initial anecdotal reports have suggested that cannabinoids might improve spasticity, and subsequently mixed results on objective measures in controlled trials may favor a benefit compared with placebo. Further studies are needed to determine benefit. 4
Weakness
Weakness is one of the most common symptoms of MS, driving the fear of many patients that they will require a wheelchair for the rest of their life. It is a major contributor to the disability seen in MS. Some strategies and treatments may improve weakness and restore functional strength. Physical therapy can sometimes be quite beneficial and improve mobility by strengthening muscles affected by disuse and promoting more efficient movements. Assistive devices,includingankle-footorthoses,canes, and walkers, can promote confidence and allow patients independence. A physiatrist can evaluate the patient for the proper use and fit of such devices and recommend specific exercise regimens to improve the function of a lost activity. Comprehensive rehabilitation programs can be very helpful as well. Similarly, aerobic exercise can improve health perception, vitality, and social interaction.
4-Aminopyridine (4-AP) acts on damaged myelin in both the central and peripheral nervous systems and has shown promise in the treatment of fatigue as well as other heat-associated disturbances in MS. 5 An oral medication, it is dosed 2 to 3 times a day with a short half-life and peak serum levels at approximately 1 hour. 6 Unlike other MS therapies, 4-AP acts directly on damaged myelin to increase saltatory conduction of electrical impulses and overcome conduction block in these nerves, which is especially prominent when temperatures are increased (heat sensitivity). This heat sensitivity occurs in approximately two-thirds of patients with MS and may be manifested by sensory, motor, and visual (Uhthoff phenomenon) disturbances as well as fatigue. 4-AP has been shown in a number of clinical trials to significantly subjectively improve symptoms of spasticity, weakness, sensory disturbances, speech impediments, and visual disturbances in patients with MS, but its use is limited by dose-related side effects, including the following (with estimated frequencies): paresthesias (20% to 100%), abdominal pain (60%), dizziness (30% to 50%), and nausea/vomiting (15%). In high doses it is thought to lower the seizure threshold, but the true incidence of this potential side effect is not established. 7 Modest benefits on strength, spasticity, and walking speed have been consistently demonstrated, although the use of this medication remains limited in part because in this form it is not a US Food and Drug Administration (FDA)-approved medication and thereby requires preparation by compounding pharmacies. Such preparations raise concerns about consistency and are subject to compounding errors, which have occasionally had serious consequences. A sustained-release formulation of 4-AP, initially called fampridine SR and now called dalfampridine-SR
KEY POINTS
A In patients with severe spasticity refractory to oral regimens or those with intolerable side effects, an intrathecal baclofen pump should be considered.
A Physical therapy can sometimes be quite beneficial and improve mobility by strengthening muscles affected by disuse and promoting more efficient movements. Assistive devices, including ankle-foot orthoses, canes, and walkers, can promote confidence and allow patients independence.
Continuum Lifelong Learning Neurol 2010;16 (5) " SYMPTOMATIC THERAPY (Ampyra), was studied in two phase 3 trials and recently was approved by the FDA. In a 14-week therapeutic treatment period study of 295 patients, 35% of dalfampridine-SR-treated patients met rigorous criteria, based on consistent improvement in walking speed as assessed by the timed 7.6-m (25-ft) walk, to be classified as responders to treatment, compared to 8% of placebo-treated patients. Patients in the trial who were classified as responders experienced on average a 25% improvement in walking speed and also noted subjective improvements in many aspects of walking. Improvements in timed 7.6-m (25-ft) walking speed are associated with greater ambulatory distances. 8 In these studies, seizures were not a significant safety signal. The dose is limited to 10 mg twice a day, approximately 12 hours apart. The tablets must not be altered in any way. The regimen must be followed exactly in order to avoid higher blood levels, which may be associated with seizures. Dalfampridine-SR is contraindicated in patients with moderate to severe renal insufficiency.
Sensory Disturbances
MS can lead to positive sensory symptoms (dysesthesia/allodynia) and negative sensory symptoms (hypesthesia). Positive sensory symptoms can often be treated with neuropathic pain medication such as antidepressants and anticonvulsants. Negative symptoms (loss of sensation) generally are not very amenable to treatment. Neuropathic pain may occur in up to 80% of patients with MS and respond well to tricyclic antidepressant medications in doses typically used to treat depression. Such medications are often limited by anticholinergic side effects of dry mouth, constipation, and drowsiness. Weight gain may also be an important adverse consequence. Off-label use of anticonvulsants such as gabapentin (Neurontin), pregabalin (Lyrica) and carbamazepine (Tegretol) can be quite effective and can have fewer side effects at their therapeutic doses. 9 Selective serotonin noradrenergic reuptake inhibitor antidepressant medications, such as duloxetine (Cymbalta), can be of benefit as well. Narcotics can also be helpful for chronic pain syndromes, but their use is often limited by side effects (eg, sedation, constipation) and concerns about addiction (Case 5-1).
Paroxysmal Symptoms
Trigeminal neuralgia occurs in approximately 2% of patients with MS and may be bilateral in up to 15% of cases associated with MS. It responds well to carbamazepine (Tegretol) in 75% of cases. 10 Medical alternatives include baclofen, phenytoin (Dilantin), gabapentin, and amitriptyline. For refractory cases, surgical treatments that can be considered but are not proven in MS include rhizotomy, microsurgical decompression, and radiosurgery.
Paroxysmal tonic spasms can be easily managed with carbamazepine (Tegretol) or oxcarbazepine (Trileptal). 11 Fatigue Fatigue in MS can be caused by a multitude of factors. Patient reports of fatigue must be carefully dissected for clues in the history that will lead to the appropriate intervention. Comorbid conditions that could lead to fatigue, such as depression, pain, sleep disorders, and concomitant medications, could be present. Fatigue sufficient to interfere with daily physical and intellectual functions occurs in 70% to 80% of patients with MS. 12 Of these patients, approximately 70% experience fatigue during part of the day, especially in the early afternoon, while approximately 30% experience constant fatigue. 12 Amantadine (Symmetrel) at a dose of 100 mg 2 times a day has been demonstrated to markedly improve this symptom above that of placebo in approximately 30% of patients in randomized controlled trials. 14 A 35-year-old woman with a history of relapsing-remitting MS, who initially had the onset of a transverse myelitis 3 years earlier with weakness in both lower extremities and numbness from the breast line down, had been diagnosed with MS. She received IV corticosteroids, and her symptoms improved but left her with considerable leg weakness and stiffness. In addition, she had painful burning sensation in her legs when she ambulated. She tried physical therapy, which initially helped her regain independence and ambulation without requiring a cane, but then she had persistent burning paresthesias in her lower extremities, stiffness in both of her legs, and painful muscle spasms at bedtime. She had been on interferon beta for the past 6 months and had noticed increased stiffness, particularly at bedtime, on the nights she took her injections. Her primary care doctor had prescribed a nighttime sleep aid to help her get through the night.
Neurologic evaluation revealed increased tone in the lower extremities bilaterally with 4/5 strength in both lower extremities, but she was able to ambulate without a cane. She had marked decreased vibratory sensation in both lower extremities. She also had increased sensation to light touch, which she likened to having a sunburn. Baclofen was prescribed, starting initially at 10 mg at bedtime, and increased to 10 mg, 3 times a day as tolerated. In addition gabapentin 300 mg was begun, initially at bedtime, and increased up to 300 mg 3 times a day.
Comment. Following an attack of transverse myelitis, patients with MS often experience burning paresthesias affecting the legs. These symptoms are typical of neuropathic pain and respond fairly well to medications, such as anticonvulsants and antidepressants. This patient was given gabapentin at the initial dose of 300 mg at bedtime. This initial treatment regimen is started at bedtime so as to target the symptoms, which seem to be worst at night. Gabapentin is very well tolerated and can be titrated up to 4800 mg daily, typically divided into 3 or 4 doses per day. In addition, baclofen 10 mg at bedtime was prescribed. A side effect of baclofen is sedation, making it an ideal choice for nighttime spasms and spasticity. Daytime dosing can be added very slowly and increased slowly to improve tolerability. The limiting factor for the use of baclofen in spasticity is weakness associated with reduced muscle tone. The medication should be titrated to benefit and reduced if worsening gait or weakness ensues. Patients with MS will not uncommonly require treatment with multiple medications to address various concomitant symptoms, some of which may be exacerbated by other medications the patient may be taking. In this case, the interferon beta may be contributing to the increase in nighttime spasticity, but she needs to continue it to keep her disease stable, so treatment of her symptoms is the preferred choice. " SYMPTOMATIC THERAPY generally considered safe for long-term use and is nonhabituating. Aspirin 650 mg twice daily recently showed benefits in a small crossover study. 15 For short-term treatment for MS-associated fatigue pemoline (Cylert), which is no longer available in the United States, may be effective in a similar number of patients. Other compounds, including methylphenidate (Ritalin) and the amphetamine mixture (Adderall), have been effective for some patients in small studies.
Modafinil (Provigil) has been studied in several multicenter controlled trials. The results of one study showed improvements; another study showed equal improvements in both treated and placebo patients. Anecdotal experience suggests that some patients have dramatic results with the medication. Armodafinil (Nuvigil), a newer compound similar to modafinil, may have some benefits as well, but no MS studies have yet been done.
Tremor
The two most common types of tremors seen in patients with MS are postural and intention. These types of tremors are believed to be caused by damage to cerebellar structures and their connections. Tremors of this nature, if severe, can be among the most disabling symptoms of MS and the most challenging to treat. Occupational therapy can sometimes be helpful to patients, allowing them to compensate with weights to dampen the amplitude of the tremor. Medications that may have some success include benzodiazepines, gabapentin, primidone, propranolol (beta-blockers), isoniazid, trazodone, and serotonin antagonists (Ondansetron). None of these medications has been proven to be very effective in large-scale clinical trials, but small studies have supported their continued use. The side effects from these medications often limit the dosing that may help relieve the tremors.
Lesions involving the thalamic (thalamotomy) or deep nuclei may have some benefits, but results have been mixed. Unilateral tremors may be more amenable to thalamic stimulation and other stereotactic surgical procedures, but long-term benefits and safety have yet to be established. 16 
Bladder Dysfunction
Bladder dysfunction caused by damage to central autonomic pathways is common in patients with MS. Urinary frequency or incontinence may be a presenting sign in up to 15% of newly diagnosed MS patients and is a major problem for over half of patients at some point throughout their course. Such dysfunction may be classified as failure to store, failure to empty (urinary retention), or a combination of both due to detrusor-sphincter dyssynergia. Failure to store, a common early problem, reflects autonomic and corticospinal tract dysfunction, often within the spinal cord. In this case, the detrusor muscle (base of the bladder) is disinhibited and undergoes contractions when the bladder is only partially filled. Since detrusor muscle contraction is responsible for bladder emptying during normal micturition when a bladder capacity of 300 mL to 400 mL is reached, premature contractions may result in premature emptying or uncomfortable spasms when bladder capacity reaches only 50 mL to 100 mL. When clinical suspicion for bladder hypertonia is high (eg, young patient with frequency, urgency), empiric treatment with anticholinergic medications is often begun without further diagnostic testing. However, when the cause of incontinence is not as clinically clear (eg, older patient with long-standing MS, significant spinal cord involvement, chronic/recurrent urinary tract infections), urologic evaluation with cystoscopy and a cystometrogram is essential to characterize the type of (5) bladder dysfunction. Kidney damage from reflux is quite rare but can be seen. Symptoms may not always reliably establish the type of dysfunction present. Measuring the postvoid bladder volume by ultrasound or catheterization can be useful in identifying patients at high risk for infections. A postvoid residual of over 100 mL is abnormally high. Scheduled voiding may be the treatment of choice initially for milder symptoms.
Anticholinergic medications such as oxybutynin (Ditropan), propantheline (Pro-Banthine), and many newer agents effectively inhibit detrusor contractions and are useful in most cases of failure of urinary storage. Typical doses for oxybutynin are 2.5 mg to 5.0 mg every day to start with, followed by titration upward to a maximum of 15 mg 3 times a day. Oxybutynin also comes in a longeracting formulation, which is typically dosed once or twice daily. Tolterodine tartrate (Detrol XL) has a very similar profile compared to oxybutynin. Tolterodine tartrate has been used for treatment of bladder spasticity at a dose of 2 mg once a day to twice a day, although no confirmed published studies on its efficacy in MS bladder management are available. Propantheline (Pro-Banthine) is used in doses ranging from 7.5 mg once a day to 30 mg 4 times a day. Typical side effects for all these anticholinergics may include drowsiness, dry mouth, and, in high doses, urinary retention. Newer agents, including solifenacin succinate (Vesicare) at 5 mg/d to 10 mg/d, have been used. For frequent urination at night, which can be very disruptive to sleep (nocturia) or long trips where it is impracticable to find a bathroom, the use of desmopressin, an analog of antidiuretic hormone, can also be helpful in reducing urinary frequency but requires regular monitoring for hyponatremia.
Failure to empty the bladder is due to muscular hypotonia and is common in long-standing MS. Cholinergic agonists, such as bethanechol (Urecholine), stimulate detrusor contractility. The initial dose is 5 mg to 10 mg and may be repeated at hourly intervals until micturition ensues or a maximal dose of 50 mg is reached. Unfortunately, bladder hypotonia is not usually responsive to pharmacologic therapy and is best managed by chronic intermittent catheterization.
Dyssynergia between the detrusor and external sphincter muscles is also common in MS and occurs when the detrusor contracts and the external sphincter fails to relax, causing urinary retention. It is difficult to treat and sometimes requires the use of anticholinergic medications to relax the detrusor and catheterizations to empty the pharmacologically relaxed bladder. Use of adrenergic blockers can be of some benefit to relax the external sphincter while the detrusor contracts (Case 5-2). Occasionally the external sphincter is surgically interrupted and an indwelling catheter is placed for drainage.
For patients with refractory incontinence, condom catheters can be helpful for men but can be irritating to the penis. Diapers are preferable to an indwelling Foley catheter, which leads to colonization of the bladder and commonly to infection. In rare circumstances, a long-term indwelling Foley catheter may be necessary for the care of the patient; in that setting, a suprapubic catheter may be a preferable option.
In all patients with bladder dysfunction the daily oral intake of urineacidifying agents, such as cranberry and orange juice, or vitamin C (1000 mg) is recommended. 17 Prophylaxis against chronic and recurrent urinary tract infections is managed additionally with nitrofurantoin (Macrodantin) at doses of 50 mg 2 to 4 times daily. This can be somewhat problematic because prophylaxis with antibiotics will ultimately lead to colonization with resistant organisms making " SYMPTOMATIC THERAPY routine treatment with regular antibiotics limited. Stronger antibiotics may be required and have worse long-term consequences. If infection occurs despite this therapy, specific agents must be used based on culture results. Methenamine hippurate (Hiprex) is a nonspecific bactericidal agent that works by the formation of formaldehyde within the bladder. It is used after the bladder has been sterilized with antibiotics, if necessary, and is not susceptible to emergence of bacterial resistance, as with nitrofurantoin. It is given at doses of 1 g twice a day, and side effects (ie, stomach upset, dysuria, and rash) are rare (4%) at these doses.
Bowel Dysfunction
MS can affect bowel function, which can be embarrassing for patients. Symptoms can include constipation, bowel urgency, and bowel incontinence. Some of the medications used to treat other symptoms may cause or aggravate bowel symptoms. Offending medications include antispasticity agents, antidepressants, anticonvulsants, anticholinergic bladder medications, and narcotics. For patients 99
Case 5-2
A 46-year-old woman with secondary progressive MS had been on therapy for the past 15 years, and her disease had been slowly getting worse with increasing gait ataxia and bladder difficulty. She described the urinary symptoms as urinary frequency, urgency, and hesitancy. She had nocturia up to 4 times per night, making it difficult for her to get a restful night of sleep. She reported excessive daytime fatigue, which impacted her job performance as a schoolteacher. Her students on a few occasions had seen her falling asleep at her desk. Her neurologic examination demonstrated mild gait ataxia and hyperreflexia. She had a postvoid residual of 200 mL of urine. She requested treatment for her urinary concerns as well as her fatigue. Modafinil 100 mg twice daily was prescribed, and she was referred to the urologist for formal urologic testing.
Comment. This case presents a challenging dilemma for the treating neurologist who would like to improve this patient's day-to-day function. Her fatigue may be related to the nocturia she is experiencing. Addressing the urinary issues will probably improve her daytime sleepiness, which may eliminate the need for medication for the fatigue. However, it is very reasonable to consider treating the fatigue while the urinary issue is addressed. Her urologic symptoms include frequency, urgency, and hesitancy. This constellation of symptoms could be related to a detrusor spasticity or a mixed picture with sphincter dyssynergia. A postvoid residual of 200 mL of urine suggests either a hypotonic bladder or a bladder outlet obstruction. Utilization of anticholinergics in this setting could exacerbate urinary retention, leading to urinary infections. With this constellation of symptoms, a formal urologic evaluation is indicated, including a urodynamic study to better delineate bladder function. Her treatment may require her to be on an intermittent catheterization regimen. Modafinil for excessive daytime drowsiness was started and may improve her daytime fatigue. Use of amantadine in this patient could lead to increased urinary retention because of its anticholinergic side effects. If the postvoid residual were less than 100 mL and a history of urinary hesitancy were absent, a trial of anticholinergic medications could be used safely.
KEY POINT
A Dyssynergia between the detrusor and external sphincter muscles is common in MS and occurs when the detrusor contracts and the external sphincter fails to relax, causing urinary retention. It is difficult to treat and sometimes requires the use of anticholinergic medications to relax the detrusor and catheterizations to empty the pharmacologically relaxed bladder. Use of adrenergic blockers can be of some benefit to relax the external sphincter while the detrusor contracts.
Continuum Lifelong Learning Neurol 2010;16 (5) with constipation, the first line of treatment is to remove the offending agents while taking additional measures. Increasing fluid and fiber intake will help as well. The natural approach, which is the most conservative approach, includes eating a diet rich in fiber, such as fruit and bran. Conservative use of over-the-counter fiber agents can be effective, but avoiding laxatives as much as possible is prudent. Overuse of these laxatives can train the bowel to evacuate only with these pharmacologic stimuli and further compound the constipation, necessitating reliance on stronger laxatives. Unfortunately, many patients must resort to these means for relief. These include docusate sodium, lactulose syrup, and polyethylene glycol, all titrated to effect. Softeners and a glycerin suppository with digital rectal stimulation can be used for the most severe situations. Stimulants, suppositories, and enemas should be used very sparingly because of the possibility of developing dependence on them.
Sexual Dysfunction
Sexual dysfunction in MS is quite common and may be uncomfortable for some patients to discuss with their physician. The most common symptoms of sexual dysfunction in women with MS include decreased sensation, decreased lubrication, and anorgasmia. 18 It may be very difficult for women to discuss with their partner and may lead to a lack of desire to have sexual relations. This can be very stressful on a marriage, leading to high rates of divorce. Sometimes, the sexual dysfunction is caused by medications used to treat a variety of symptoms of MS, including antidepressants, anticonvulsants, and bladder medications. The first step in evaluating a patient is for the health care provider to open a dialogue with the patient to discuss what issues may be present. Initial strategies include removing any known offending agents and determining whether any secondary causes that can be identified and addressed are present. Including the partner in the discussion will greatly enhance success. Sexual counseling and foreplay may be helpful for stimulation and lubrication. Synthetic lubricants are also beneficial.
Men with MS may have erectile dysfunction, anorgasmia, and decreased desire as well. The same general principles for women apply to men with a few sex-specific treatments. Again, discontinuing of contributing medications, counseling, and foreplay may be helpful for all of these symptoms. Sildenafil (Viagra) has been shown to be effective for erectile dysfunction in a randomized placebo-controlled study in men with MS. Other phosphodiesterase inhibitors such as vardenafil (Levitra) and tadalafil (Cialis) are approved for erectile dysfunction in men but have not been extensively studied in MS. They seem to be effective in clinical practice (anecdotal information). In women, phosphodiesterase inhibitors may improve lubrication but do not affect overall sexual function.
Affective Symptoms
Depression is extremely common in patients with MS; it has been reported that greater than 50% of patients will suffer from depression during the course of the disease. This can be in part a situational depression associated with having a chronic disease and disability and is probably also as a result of the underlying brain disease and inflammation. Some of the disease-modifying medications, in particular interferon beta, may contribute to depression. Treatments for depression in MS utilize the same approaches that are helpful for depression and anxiety in the general population. " SYMPTOMATIC THERAPY can be socially disabling. It can be successfully treated with low doses of tricyclic antidepressants or a combination of dextromethorphan and quinidine. 19 A randomized controlled trial of dextromethorphan plus quinidine for pseudobulbar affect in MS has been completed and is awaiting publication.
Cognitive Impairment
Cognitive impairment may be caused by the lesions in the brain, but may be also be secondary to other factors, such as the medications used to treat symptoms from MS, fatigue, or depression. The first step in managing patients with cognitive impairment is to rule out factors other than MS that might be contributing to the concern of cognitive impairment. Depression and anxiety can be quite common symptoms in MS and can present with cognitive issues. Complicating matters is that these concerns are self-reported and can be unreliable. Family members or coworkers are often more informative and tend to be more accurate, but formal neuropsychological testing is the standard for identifying the true severity of cognitive deficits. Medications, especially those causing sedation or anticholinergic side effects, may also contribute to this impairment. 20 The first step is to remove these medications from the patient's regimen and determine cause and effect. The next step in helping patients with cognitive impairment is the development of compensatory strategies. After a detailed battery of tests is performed, a rehabilitation plan can be initiated. The plan encompasses a wide variety of approaches, including external (eg, writing in notebooks, keeping calendars, computers, and PDAs) and internal aids (eg, instruction in the use of mnemonics and visual associations). Donepezil (Aricept) had been found in an earlier trial to possibly improve verbal memory in mild impairment. 21 However, a re-cently reported larger placebo-controlled randomized trial failed to show a benefit of donepezil. 22 
OTHER COMPLICATIONS
Patients with MS experience a multitude of other medical issues that are sometimes beyond the expertise of the neurologist as treating physician but should be recognized as complications of the disease. Appropriate identification and referral for diagnostic tests and therapeutic interventions can improve patients' quality of life. Other medical complications of MS include osteopenia; skin breakdown from consequences of immobility, including decubitus ulcers; and swallowing dysfunction and aspiration, most commonly occurring in patients with advanced disability, especially those who are bedridden.
Osteopenia
Bone loss can be a very serious problem for patients with MS. Several circumstances lead to bone loss, including immobility, corticosteroid use, and the disease itself, perhaps from inflammatory cytokines that can activate osteoclasts. As the disease evolves from the early stages, the cause for bone loss may change. Initially, corticosteroids for relapses predominate as the potential cause, followed later by immobility issues. Maximizing weight-bearing activities will help prevent further bone loss, which is especially important with concomitant steroid use. Men and women undergoing frequent steroid treatment should be routinely evaluated with a dual-energy x-ray absorptiometry (DEXA) scan for bone density. Close monitoring and standard treatment for osteoporosis (eg, bisphosphonates) are appropriate. 23 
Decubitus Ulcers
As MS evolves, a tendency for complications of immobility emerges. These complications can include decubitus ulcers, which are caused by pressure and immobility on areas of skin that are points of constant pressure. They are typically found in patients who are wheelchair bound or bedbound. The most common locations for these decubitus ulcers are on skin over the sacrum, ischial tuberosities, greater trochanters, and heels. It is very important to aggressively treat these skin breakdowns because of potential lifethreatening infections, such as cellulitis and osteomyelitis. 24 The mainstay of prevention is to avoid constant pressure by frequently changing positions and reducing pressure on the skin most at risk. Patients with this level of disability commonly do not have adequate nutritional intake, which contributes to poor wound healing. Nutritional status should be maximized, and use of medications that inhibit wound healing, such as corticosteroids, should be minimized. When breakdown occurs, avoiding pressure at the wound site is paramount and use of topical creams and keeping the site clean are key to proper wound healing. Sometimes the use of specialized bedding, including air mattresses, will be required. Wound specialists and plastic surgeons can be helpful for establishing the optimal care plan. 25 Dysphagia Dysphagia can occur at any time in patients with MS and lead to embarrassment and weight loss. It is especially common in patients with greater disability. Initial symptoms may include choking on tough solids but can evolve into difficulty with liquids as well. Often dysphagia may be asymptomatic and only picked up by a swallowing study or by a speech therapist. Mild to moderate dysphagia can usually be treated successfully with behavioral and dietary modifications, including eating only while upright, flexing the neck before swallowing, taking smaller bites, and thickening liquids. Severe dysphagia may require a feeding tube to prevent aspiration. These patients are at high risk for aspiration pneumonias. 26 
CONCLUSION
Treatment of MS requires a multidisciplinary approach. The disease requires treatment of acute relapses, prevention of new events, and management of emerging and ongoing symptoms. Data for treatment of acute relapses are available, but data for the management of MS symptoms are sparse. Most of the practice of MS is more of an art than a science. Many years of trial and error have given clinicians strategies with which to work. The goal of treating symptoms in MS is to improve the quality of life for the individual; currently no standardized regimen exists. Nevertheless, treating symptoms in patients with MS will continue to be an important part of their comprehensive care. The future is bright with newer treatments impacting the disease in positive ways, and it is hoped that treatments that repair CNS damage will be developed.
KEY POINT
A The goal of treating symptoms in MS is to improve the quality of life for the individual; currently no standardized regimen is available.
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